Baral Ranju, Knudson Sophia, Barros Iracema, Cofie Patience, Dapaah Patience, Khan Sadaf, Kumar Sandeep, Mehedi Kamran, Newhouse Lauren, Otiang Elkanah, Owusu Rosemond, Pecenka Clint, Picolo Melanie, Pinto Judite, Quelhas Diana, Routray Satyabrata, Uranw Surendra, Fleming Jessica A
Center for Vaccine Innovation and Access, PATH, Seattle, USA.
Primary Health Care, PATH, Seattle, USA.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2437258. doi: 10.1080/21645515.2024.2437258. Epub 2024 Dec 17.
New respiratory syncytial virus (RSV) maternal vaccines have begun roll out in some countries, with efforts in progress to broaden access worldwide and shorten the timeline to access for low- and middle-income countries (LMICs). Prior to new maternal immunization (MI) introductions, countries will need to evaluate their capacity and readiness for successful introduction. The World Health Organization's Maternal Immunization and Antenatal Care Situation Analysis (MIACSA) project (2016-2019) developed a checklist for countries to self-evaluate their capacity to introduce new maternal vaccines. Here, we report on our use of the MIACSA checklist in Bangladesh, Ghana, Kenya, Mozambique, and Nepal to gather country stakeholders' perceptions of MI readiness and provide additional considerations for implementers when using the checklist to optimize its usefulness.
新型呼吸道合胞病毒（RSV）孕产妇疫苗已在一些国家开始推广，目前正在努力扩大全球可及性，并缩短低收入和中等收入国家（LMICs）的获取时间线。在引入新的孕产妇免疫（MI）措施之前，各国需要评估其成功引入的能力和准备情况。世界卫生组织的孕产妇免疫和产前保健情况分析（MIACSA）项目（2016 - 2019年）为各国制定了一份自我评估引入新型孕产妇疫苗能力的清单。在此，我们报告我们在孟加拉国、加纳、肯尼亚、莫桑比克和尼泊尔使用MIACSA清单的情况，以收集各国利益相关者对孕产妇免疫准备情况的看法，并为实施者在使用该清单以优化其效用时提供更多考虑因素。
